INmune Bio Inc INMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INMB is a good fit for your portfolio.
News
-
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
-
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
-
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
-
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
-
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
-
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
-
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Trading Information
- Previous Close Price
- $10.57
- Day Range
- $10.23–11.12
- 52-Week Range
- $6.52–14.66
- Bid/Ask
- $10.60 / $10.71
- Market Cap
- $194.59 Mil
- Volume/Avg
- 89,718 / 103,201
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,176.33
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.inmunebio.com
Comparables
Valuation
|
Metric
|
INMB
|
ITOS
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.77 | 0.66 | 1.79 |
Price/Sales | 1,176.33 | 30.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
INMB
ITOS
CGEM
Financial Strength
|
Metric
|
INMB
|
ITOS
|
CGEM
|
|---|---|---|---|
Quick Ratio | 2.07 | 13.46 | 16.60 |
Current Ratio | 2.16 | 13.76 | 17.07 |
Interest Coverage | −12.17 | — | — |
Quick Ratio
INMB
ITOS
CGEM
Profitability
|
Metric
|
INMB
|
ITOS
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −32.79% | −12.92% | −24.60% |
Return on Equity (Normalized) | −45.48% | −14.67% | −25.95% |
Return on Invested Capital (Normalized) | −31.98% | −18.54% | −29.67% |
Return on Assets
INMB
ITOS
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tcqjcznl | Hlpy | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gqgfptpfk | Gscgpl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Njbhfgnd | Cywbzy | $99.5 Bil | |
MRNA
| Moderna Inc | Ydwzggph | Czmyj | $38.8 Bil | |
ARGX
| argenx SE ADR | Wqxyvzzxl | Jngtj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nrxccvkp | Vpk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gpckrhcd | Mchvk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lffdkyxzf | Hjpmbz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wczggjpghl | Gvkgg | $12.5 Bil | |
INCY
| Incyte Corp | Zfxrbwpv | Gmkhcgj | $11.6 Bil |